Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Sponsor: Boehringer Ingelheim
A PHASE3 clinical study on Atrial Fibrillation and Stroke, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 9 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Population Health Research Institute
- Uppsala University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands, Aalborg, Denmark, Aalst, Belgium, Aarhus C, Denmark, Abbeville, France, Abeno-ku, Osaka, Osaka, Japan, Adana, Turkey (Türkiye), Afula, Israel, Ahmedabad, India, Ajax, Canada and 695 more location s